Best for
Mobile

Posted
Charles River Laboratories International, Inc is a diagnostics & research business based in the US. Charles River Laboratories International shares (CRL.US) are listed on the NYSE and all prices are listed in US Dollars. Charles River Laboratories International employs 17,100 staff and has a trailing 12-month revenue of around $2.8 billion.
Best for
Mobile
Best for
Low-cost
Best for
All rounder
Best for
Beginners
Latest market close | $N/A |
---|---|
52-week range | $95.58 - $284.6 |
50-day moving average | $255.1461 |
200-day moving average | $228.4667 |
Wall St. target price | $265.71 |
PE ratio | 46.72 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $5.997 |
Other fees may apply. Your capital is at risk.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Charles River Laboratories International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Charles River Laboratories International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Charles River Laboratories International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, Charles River Laboratories International shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Charles River Laboratories International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0389. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Charles River Laboratories International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Charles River Laboratories International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $656.8 million.
The EBITDA is a measure of a Charles River Laboratories International's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $2.8 billion |
---|---|
Operating margin TTM | 15.26% |
Gross profit TTM | $965 million |
Return on assets TTM | 5.5% |
Return on equity TTM | 17.28% |
Profit margin | 10.68% |
Book value | $38.14 |
Market capitalisation | $13.9 billion |
TTM: trailing 12 months
There are currently 688,572 Charles River Laboratories International shares held short by investors – that's known as Charles River Laboratories International's "short interest". This figure is 17.1% up from 587,798 last month.
There are a few different ways that this level of interest in shorting Charles River Laboratories International shares can be evaluated.
Charles River Laboratories International's "short interest ratio" (SIR) is the quantity of Charles River Laboratories International shares currently shorted divided by the average quantity of Charles River Laboratories International shares traded daily (recently around 271091.33858268). Charles River Laboratories International's SIR currently stands at 2.54. In other words for every 100,000 Charles River Laboratories International shares traded daily on the market, roughly 2540 shares are currently held short.
However Charles River Laboratories International's short interest can also be evaluated against the total number of Charles River Laboratories International shares, or, against the total number of tradable Charles River Laboratories International shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Charles River Laboratories International's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Charles River Laboratories International shares in existence, roughly 10 shares are currently held short) or 0.0158% of the tradable shares (for every 100,000 tradable Charles River Laboratories International shares, roughly 16 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Charles River Laboratories International.
Find out more about how you can short Charles River Laboratories International stock.
We're not expecting Charles River Laboratories International to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Charles River Laboratories International's shares have ranged in value from as little as $95.58 up to $284.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Charles River Laboratories International's is 1.1171. This would suggest that Charles River Laboratories International's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Subscribe to trending stock alerts for a chance to win
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.